Ranked #4,683 of 8,699 institutional investors
Great Point Partners LLC
Greenwich, CT
$334M
US stock portfolio at live prices · today −$390K (−0.12%)
Market closed. Prices as of Nov 20, 8:11 AM ET
- Value at quarter end (Q3 2026)
- $381M
- Change from Q2 2026
- −$43.5M (−10.25%)
- Positions
- 32 · 5 new, 5 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: call options on $4.4M of stock, put options on $33.1M. $66.8M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesGMAB 8.07%VERA 6.48%VOR 6.25%SGMT 5.65%AMLX 5.49%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| GMAB Genmab A/S | 525,000 | $27.0M | 8.07% | New |
| VERA Vera Therapeutics, Inc. | 808,717 | $21.6M | 6.48% | Added +35% |
| VOR Vor Biopharma Inc. | 1,126,910 | $20.9M | 6.25% | Reduced −34% |
| SGMT Sagimet Biosciences Inc. | 1,961,701 | $18.9M | 5.65% | Reduced −3% |
| AMLX Amylyx Pharmaceuticals, Inc. | 700,000 | $18.3M | 5.49% | Unchanged |
| LBRX LB Pharmaceuticals Inc | 410,420 | $16.4M | 4.92% | Added +29% |
| DFTX Definium Therapeutics, Inc. | 508,735 | $15.0M | 4.49% | Added +20% |
| ABVX ABIVAX Société Anonyme | 155,000 | $12.5M | 3.74% | Reduced −24% |
| ANNX Annexon, Inc. | 3,500,000 | $11.9M | 3.57% | Unchanged |
| IONS Ionis Pharmaceuticals, Inc. | 420,000 | $11.4M | 3.42% | New |
| BLTE Belite Bio, Inc | 75,000 | $11.3M | 3.39% | New |
| MLTX MoonLake Immunotherapeutics | 855,813 | $9.4M | 2.83% | Unchanged |
| CLYM Climb Bio Inc | 800,000 | $7.4M | 2.22% | Reduced −20% |
| EPRX Eupraxia Pharmaceuticals Inc. | 1,200,000 | $7.3M | 2.20% | Unchanged |
| NGNE Neurogene Inc. | 300,000 | $6.9M | 2.06% | Reduced −15% |
| ABCL AbCellera Biologics Inc. | 600,000 | $6.3M | 1.88% | New |
| NKTR Nektar Therapeutics | 175,000 | $5.7M | 1.71% | Unchanged |
| CMPS COMPASS Pathways plc | 500,000 | $4.3M | 1.30% | New |
| RZLT Rezolute, Inc. | 951,809 | $4.0M | 1.20% | Unchanged |
| ELVN Enliven Therapeutics, Inc. | 70,000 | $3.2M | 0.97% | Unchanged |
| IRD Opus Genetics, Inc. | 776,881 | $3.2M | 0.95% | Reduced −61% |
| CGEM Cullinan Therapeutics, Inc. | 300,000 | $2.7M | 0.81% | Unchanged |
| RLMD Relmada Therapeutics, Inc. | 842,106 | $2.6M | 0.78% | Unchanged |
| SCYX SCYNEXIS, Inc. | 944,292 | $2.5M | 0.74% | Unchanged |
| ALT Altimmune, Inc. | 1,741,232 | $2.5M | 0.74% | Unchanged |
| ORKA Oruka Therapeutics, Inc. | 24,649 | $2.4M | 0.72% | Reduced −87% |
| DBVT DBV Technologies S.A. | 250,000 | $2.4M | 0.71% | Added +59% |
| EVMN Evommune Inc | 325,000 | $2.4M | 0.70% | Unchanged |
| DRUG Bright Minds Biosciences Inc. | 109,603 | $2.3M | 0.68% | Unchanged |
| HUMA Humacyte, Inc. | 3,750,000 | $2.0M | 0.61% | Unchanged |
| CTNM Contineum Therapeutics, Inc. | 186,183 | $1.7M | 0.50% | Reduced −80% |
| RNTX Rein Therapeutics Inc. | 1,663,144 | $612K | 0.18% | Reduced −35% |